NDATOPICALSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action for ESKATA for the treatment of seborrheic keratosis is unknown. 12.2 Pharmacodynamics The pharmacodynamics of ESKATA in the treatment of seborrheic keratosis are unknown. 12.3 Pharmacokinetics Following application of…
Indications (1)
Clinical Trials (1)
KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response
Started Jan 2017
12 enrolled
Breast Cancer
Loss of Exclusivity
LOE Date
Jul 4, 2035
113 months away
Patent Expiry
Jul 4, 2035